Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposes PMAs For Pelvic Organ Prolapse Mesh Devices

This article was originally published in The Gray Sheet

Executive Summary

FDA is proposing class III, PMA status for surgical mesh used to treat pelvic organ prolapse based on evidence of health risks including mesh exposures and extrusions, pelvic pain, infections and repeat surgery for complications.

You may also be interested in...



PMA Mandate Set For Pelvic Organ Prolapse Transvaginal Mesh

FDA issued final orders up-classifying surgical mesh for transvaginal repair of pelvic organ prolapse from class II to class III and calling for PMA standards, including clinical trial, animal studies, and materials testing data from new and existing manufacturers.

FDA Advisors Call For New Cleaning Methods, Sterilization For Duodenoscopes

Current reprocessing methods for duodenoscopes provide no reasonable assurance of safety and effectiveness, and manual cleaning steps need improvement, an FDA panel said. Most panelists called for upgrading manual cleaning, followed by lengthy sterilization of the products until they can be redesigned.

Boston Scientific Will Settle Some Transvaginal Surgical Mesh Suits For $119 Mil.

The company announced April 28 that it has settled 2,970 transvaginal surgical mesh device patient lawsuits, but upwards of 25,000 cases or claims against Boston Scientific are still active.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel